Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Displaying Results 31 - 45 of 74
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced non-squamous non-small cell lung cancer. We
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses whether immunotherapy works in patients with driver mutations like EGFR and ALK. We thank the
For this series, GRACE sat down with Marco Ruiz, MD, an oncologist at Memorial Cancer Institute specializing in hematologic or blood cancers, including leukemia, lymphoma, myelodysplastic syndrome (MDS) and myelofibrosis. He is also an experienced bone marrow transplant specialist and is active in
Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of immunotherapy for previously treated patients with non-small cell lung cancer.
In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for second-line treatment.
In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for first-line treatment.
In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy combined.
Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy with chemotherapy.
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses the role for immunotherapy in patients with a driver mutation.
Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses if immunotherapy should stop in responding patients after a fixed duration of treatment.
GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there a preferred induction therapy (¿¿Hay alguna terapia de inducción preferida?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and
GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding the new antibodies for multiple myeloma (MM) therapy (¿Cuáles son los anticuerpos nuevos para la terapia del mieloma múltiple (MM)?). Stay tuned for more on our continuing video series with our Spanish speaking
GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding whether all patients should receive an autologous transplant (¿Todos deberían de recibir un trasplante autólogo?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in
GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there is a best maintenance therapy (¿Existe una terapia de mantenimiento mejor sobre las demás?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.